$INNV PR $0.253 mutiple support 'bottom' Rentr
Post# of 98041
Posted On: 12/02/2016 5:09:42 PM
$INNV PR $0.253
mutiple support 'bottom'
Rentry last week
$0.2549
Flag support
multi-bagger corrected
OTC
100% Sell
Barchart
Might be 1st time I've recommended a 100% Sell
Last ten trades
Website
12/1/16 Innovus Pharma Launches its Clinically Proven UriVarx™ Product
for Bladder Health Through its Beyond Human® Sales and Marketing
Platform in the United States
11/29/16 Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
Nov 21, 2016 Innovus Pharma Launches Zestra® Multi-Dose Form for Female Sexual Arousal in the U.S. Press Release
Nov 18, 2016 Innovus Pharma (INNV) Continues to Execute with Record Q3 '16 Revenue -- SECFilings.com Press Release
Nov 10, 2016 Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016, Increasing 947% to $1.9 Million, and Record Nine Months Ended September 2016 Revenues, Increasing 463% to $3.1 Million Press Release
Nov 8, 2016 Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon Press Release
Nov 7, 2016 Innovus Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Thursday, November 10, 2016 Press Release
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
mutiple support 'bottom'
Rentry last week
$0.2549
Flag support
multi-bagger corrected
OTC
100% Sell
Barchart
Might be 1st time I've recommended a 100% Sell
Last ten trades
Website
12/1/16 Innovus Pharma Launches its Clinically Proven UriVarx™ Product
for Bladder Health Through its Beyond Human® Sales and Marketing
Platform in the United States
11/29/16 Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
Nov 21, 2016 Innovus Pharma Launches Zestra® Multi-Dose Form for Female Sexual Arousal in the U.S. Press Release
Nov 18, 2016 Innovus Pharma (INNV) Continues to Execute with Record Q3 '16 Revenue -- SECFilings.com Press Release
Nov 10, 2016 Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016, Increasing 947% to $1.9 Million, and Record Nine Months Ended September 2016 Revenues, Increasing 463% to $3.1 Million Press Release
Nov 8, 2016 Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon Press Release
Nov 7, 2016 Innovus Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Thursday, November 10, 2016 Press Release
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
(2)
(0)Scroll down for more posts ▼